(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, ...

In this article, we will discuss 3 top dividend stocks with yields above 4% that could be attractive buys in the fall of 2025 ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...

Adequate management of COPD is important because hospitalisation for an acute exacerbation of COPD (AECOPD) is associated ...

Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of ...

CNW/ - This RSV season, eight out of 10 Canadian newborns and infants will have access to Beyfortus, the first and only protective antibody approved in Canada for the prevention of RSV lower ...

Monday, November 10, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture ...

A recently launched campaign starring patients and scientists shows Sanofi in hot pursuit of scientific innovation. | A ...

Sanofi’s ‘A Trusted Circle,’ made with Republica Havas Health, won bronze for Purpose-led Campaign of the Year among ...

Sanofi's “Badge of Honor,” made with FCB Health New York, won gold for Data-Driven Campaign of the Year among suppliers, ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...